GDTC logo

CYTOMED THERAPEUTICS LTD

GDTCNASDAQ
πŸ† #4863 by market capEarnings May 3US Equity
$0.76β–Ό $0.02 (βˆ’2.33%)
Market closed Β· at close
πŸ””
Track GDTC
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 2.3%
7dβ–Ό 9.0%
14dβ–Ό 15.3%
30dβ–Ό 12.1%
ytdβ–Ό 44.5%
1yβ–Ό 60.7%
🏦Market Cap
$9M
Small Cap
πŸ“ˆRevenue Growth (YoY)
44.5%
High Growth
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
36.2x
Expensive
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.71 – $0.79
52-Week Range
β€”
Volume (shares)
15,478
Avg Volume (shares)
β€”
Shares Outstanding
11.9M
Next Earnings
2027-05-03

Fundamentals Snapshot

Annual Revenue
$324,387
Last Q Revenue
$157,289
P/E Ratio
β€”
P/S Ratio
36.2x
EPS (TTM)
β€”
Dividend Yield
β€”
Dilution (1yr)
+0.9%
GDTC logo

CYTOMED THERAPEUTICS LTD

GDTC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$324Kβ–² +366.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
79.0%β–² +4.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$5Mβ–² +33.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$4Mβ–² +7.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
11.6Mβ–² +0.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2Mβ–Ό βˆ’$3M YoY
StockOtter Β· stockotter.space

About CYTOMED THERAPEUTICS LTD

CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Jul 2025

Latest News & Updates

News unavailable.